Live Breaking News & Updates on சர்வதேச இரத்தம்

Stay updated with breaking news from சர்வதேச இரத்தம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Xenikos Announces T-Guard® Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives


Share:
Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard
® Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second Half of 2021
Positive Results Expected to Support Both FDA and EMA Regulatory Submissions
NIJMEGEN, the Netherlands, July 19, 2021 (GLOBE NEWSWIRE) Xenikos B.V., a privately-held biotechnology company that develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection, today announced that it has reached agreement with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the design of its pivotal randomized Phase 3 clinical study (BMT CTN 2002) to evaluate T-Guard ....

United States , France General , John Levine , Gabrielle Meyers , Ypke Van Oosterhout , Sam Martin Carrie Mckim , Mehdi Hamadani , Professor Of The Department Hematology , National Cancer Institute , Core Transplant Centers Consortia , Marrow Transplant Research , International Blood , Oregon Health , Clinical Research , Blood Institute , Sinai School Of Medicine , National Heart , Company Plans To Commence New Pivotal , Science University , Emmes Company , National Institutes Of Health , Drug Administration , National Marrow Donor Program , College Of Wisconsin , Marrow Transplant Clinical Trials Network , European Medicines Agency ,

Xenikos B.V.: Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives


Xenikos B.V.: Xenikos Announces T-Guard Phase 3 Clinical Update and Outlines 2021-2022 Corporate Objectives
Company Plans to Commence New Pivotal, Randomized Phase 3 Study Evaluating T-Guard
Versus Ruxolitinib in Patients with Grade III or IV Steroid-refractory Acute Graft-Versus-Host Disease in Second Half of 2021
Positive Results Expected to Support Both FDA and EMA Regulatory Submissions
NIJMEGEN, the Netherlands, July 19, 2021 (GLOBE NEWSWIRE) Xenikos B.V., a privately-held biotechnology company that develops innovative immunotherapies for treating patients with severe immune disease and post-transplant rejection, today announced that it has reached agreement with the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) on the design of its pivotal randomized Phase 3 clinical study (BMT CTN 2002) to evaluate T-Guard ....

United States , France General , John Levine , Gabrielle Meyers , Kostenloser Wertpapierhandel , Ypke Van Oosterhout , Sam Martin Carrie Mckim , Mehdi Hamadani , Professor Of The Department Hematology , National Cancer Institute , Core Transplant Centers Consortia , Marrow Transplant Research , International Blood , Oregon Health , Clinical Research , Blood Institute , Sinai School Of Medicine , National Heart , Company Plans To Commence New Pivotal , Science University , Emmes Company , National Institutes Of Health , Drug Administration , National Marrow Donor Program , College Of Wisconsin , Marrow Transplant Clinical Trials Network ,